Silencing of ECHDC1 inhibits growth of gemcitabine‑resistant bladder cancer cells

Asai,Seiji; Miura,Noriyoshi; Sawada,Yuichiro; Noda,Terutaka; Kikugawa,Tadahiko; Tanji,Nozomu; Saika,Takashi

doi:10.3892/ol.2017.7269

Silencing of ECHDC1 inhibits growth of gemcitabine‑resistant bladder cancer cells

Authors:
- Seiji Asai
- Noriyoshi Miura
- Yuichiro Sawada
- Terutaka Noda
- Tadahiko Kikugawa
- Nozomu Tanji
- Takashi Saika
View Affiliations

Affiliations: Department of Urology, Ehime University Graduate School of Medicine, Toon, Ehime 791‑0295, Japan, Department of Urology, Houshasen‑Daiichi Hospital, Imabari, Ehime 794‑0054, Japan
Published online on: October 26, 2017 https://doi.org/10.3892/ol.2017.7269
Pages: 522-527

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Combined gemcitabine and cisplatin (GC) treatment is a first line chemotherapy for bladder cancer. However, acquired resistance to GC has been a major problem. To address the mechanism of gemcitabine resistance, and to identify potential biomarkers or target proteins for its therapy, we aimed to identify candidate proteins associated with gemcitabine resistance using proteomic analysis. We established gemcitabine‑resistant human bladder cancer cell lines (UMUC3GR and HT1376GR) from gemcitabine‑sensitive human bladder cancer cell lines (UMUC3 and HT1376). We compared the protein expression of parental and gemcitabine‑resistant cell lines using isobaric tags for relative and absolute quantification (iTRAQ) and liquid chromatography tandem mass spectrometry. Among the identified proteins, ethylmalonyl‑CoA decarboxylase (ECHDC1) expression was significantly increased in both of the gemcitabine‑resistant cell lines compared to the respective parental cell lines. Silencing of ECHDC1 reduced ECHDC1 expression and significantly inhibited the proliferation of UMUC3GR cells. Furthermore, silencing of ECHDC1 induced upregulation of p27, which is critical for cell cycle arrest in the G1 phase, and induced G1 arrest. In conclusion, ECHDC1 expression is increased in gemcitabine‑resistant bladder cancer cells, and is involved in their cell growth. ECHDC1, which is a metabolite proofreading enzyme, may be a novel potential target for gemcitabine‑resistant bladder cancer therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global Cancer Statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000. View Article : Google Scholar : PubMed/NCBI
3	Tanji N, Ozawa A, Miura N, Yanagihara Y, Sasaki T, Nishida T, Kikugawa T, Ikeda T, Ochi T, Shimamoto K, et al: Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol. 15:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
4	Lee DH, Chung K, Song JA, Kim TH, Kang H, Huh JH, Jung SG, Ko JJ and An HJ: Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J Proteome Res. 9:5668–5676. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sun QL, Sha HF, Yang XH, Bao GL, Lu J and Xie YY: Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol. 137:521–532. 2011. View Article : Google Scholar : PubMed/NCBI
6	Nishimura K, Tsuchiya Y, Okamoto H, Ijichi K, Gosho M, Fukayama M, Yoshikawa K, Ueda H, Bradford CR, Carey TE and Ogawa T: Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma. Br J Cancer. 111:799–806. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et al: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 3:1154–1169. 2004. View Article : Google Scholar : PubMed/NCBI
8	Bang D, Wilson W, Ryan M, Yeh JJ and Baldwin AS: GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov. 3:690–703. 2013. View Article : Google Scholar : PubMed/NCBI
9	Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, et al: mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA. 111:pp. 409–414. 2014; View Article : Google Scholar : PubMed/NCBI
10	Yang Y, Chen Y, Saha MN, Chen J, Evans K, Qiu L, Reece D, Chen GA and Chang H: Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia. 29:715–726. 2015. View Article : Google Scholar : PubMed/NCBI
11	Linster CL, Noël G, Stroobant V, Vertommen D, Vincent MF, Bommer GT, Veiga-da-Cunha M and Van Schaftingen E: Ethylmalonyl-CoA decarboxylase, a new enzyme involved in metabolite proofreading. J Biol Chem. 286:42992–43003. 2011. View Article : Google Scholar : PubMed/NCBI
12	Van Schaftingen E, Rzem R, Marbaix A, Collard F, Veiga-da-Cunha M and Linster CL: Metabolite proofreading, a neglected aspect of intermediary metabolism. J Inherit Metab Dis. 3:427–434. 2013. View Article : Google Scholar
13	Mounier C, Bouraoui L and Rassart E: Lipogenesis in cancer progression (Review). Int J Oncol. 45:485–492. 2014.PubMed/NCBI
14	Bettey M, Ireland RJ and Smith AM: Purification and characterization of acetyl CoA carboxylase from developing pea embryos. J Plant Physiol. 140:513–520. 1992. View Article : Google Scholar
15	Miller AL and Levy HR: Acetyl-CoA carboxylase from rat mammary gland. EC 6.4.1.2 acetyl-CoA: Carbon dioxide ligase (ADP). Methods Enzymol. 35:11–17. 1975. View Article : Google Scholar : PubMed/NCBI
16	Waite M and Wakil SJ: Studies on the mechanism of fatty acid synthesis: XII. Acetyl coenzyme A carboxylase. J Biol Chem. 237:2750–2757. 1962.PubMed/NCBI
17	Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, et al: Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci USA. 105:pp. 4340–4345. 2008; View Article : Google Scholar : PubMed/NCBI
18	Schuck PF, Busanello EN, Moura AP, Tonin AM, Grings M, Ritter L, Vargas CR, da Costa Ferreira G and Wajner M: Promotion of lipid and protein oxidative damage in rat brain by ethylmalonic acid. Neurochem Res. 35:298–305. 2010. View Article : Google Scholar : PubMed/NCBI
19	Schuck PF, Milanez AP, Felisberto F, Galant LS, Machado JL, Furlanetto CB, Petronilho F, Dal-Pizzol F, Streck EL and Ferreira GC: Brain and muscle redox imbalance elicited by acute ethylmalonic acid administration. PLoS One. 10:e01266062015. View Article : Google Scholar : PubMed/NCBI
20	Albright CD, Klem E, Shah AA and Gallagher P: Breast cancer cell-targeted oxidative stress: Enhancement of cancer cell uptake of conjugated linoleic acid, activation of p53, and inhibition of proliferation. Exp Mol Pathol. 79:118–125. 2005. View Article : Google Scholar : PubMed/NCBI
21	Quintos L, Lee IA, Kim HJ, Lim JS, Park J, Sung MK, Seo YR and Kim JS: Significance of p27 as potential biomarker for intracellular oxidative status. Nutr Res Pract. 4:351–355. 2010. View Article : Google Scholar : PubMed/NCBI
22	Lee J and Kim SS: The function of p27 KIP1 during tumor development. Exp Mol Med. 41:765–771. 2009. View Article : Google Scholar : PubMed/NCBI
23	Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8:9–22. 1994. View Article : Google Scholar : PubMed/NCBI
24	Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI